The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2
Townsend JP, Hassler HB, Sah P, Galvani AP, Dornburg A. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2204336119. PMID: 35858382, PMCID: PMC9351502, DOI: 10.1073/pnas.2204336119.Peer-Reviewed Original ResearchThe durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, Ruddle NH, Galvani AP, Dornburg A. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. The Lancet Microbe 2021, 2: e666-e675. PMID: 34632431, PMCID: PMC8486316, DOI: 10.1016/s2666-5247(21)00219-6.Peer-Reviewed Original ResearchConceptsDurability of immunitySARS-CoV-2Human-infecting coronavirusesProbability of reinfectionAntibody levelsMERS-CoVSARS-CoVLong-term immune responsePeak antibody responsePublic health decision makingCOVID-19 pandemic continuesEndemic conditionsCOVID-19 morbidityPublic health measuresVirus SARS-CoVHealth decision makingOptical density levelsDevastating COVID-19 pandemicAntibody declineLikely reinfectionAntibody responseEndemic coronavirusesHCoV-NL63Immune responseHuman coronavirusesInfection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments
Townsend J, Hassler H, Emu B, Dornburg A. Infection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments. Journal Of The National Cancer Institute 2023, 115: 1626-1628. PMID: 37599438, PMCID: PMC10699797, DOI: 10.1093/jnci/djad158.Peer-Reviewed Original ResearchConceptsReinfection riskAntineoplastic therapyAntibody dataSARS-CoV-2 infectionSARS-CoV-2 vaccinesChemotherapy-immunotherapy combinationsPfizer-BioNTech BNT162b2COVID-19 vaccinationHigh infection riskFrequent boostingRituximab therapyBreakthrough infectionsVaccination scheduleAntibody levelsBooster scheduleVaccination frequencyImmune responseAdditional interventionsReduced riskHigh riskHormonal treatmentGeneral populationNecessitating assessmentPatientsInfection riskInfection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend J, Hassler H, Dornburg A. Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting. Journal Of Medical Virology 2023, 95: e28461. PMID: 36602045, DOI: 10.1002/jmv.28461.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Anti-spike IgG antibodiesWaning of antibodiesVaccine boostingBooster vaccinationBreakthrough infectionsAntibody levelsIgG antibodiesMRNA vaccinesProbability of infectionInfectionEndemic transmissionIndividual infectionsPredominant variantCOVID-19 pandemicMessenger RNAAntibodiesDisease spreadBNT162b2HospitalizationMorbidityVaccinationWidespread uptakeVaccineMortality